Smoking cessation and outcome after ischemic stroke or TIA

Katherine A Epstein; Catherine M Viscoli; J David Spence; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Brett Gerstenhaber; Peter D Guarino; Anand Dixit; Karen L Furie; Walter N Kernan; IRIS Trial Investigators

doi:10.1212/WNL.0000000000004524

Smoking cessation and outcome after ischemic stroke or TIA

Standard

Smoking cessation and outcome after ischemic stroke or TIA. / Epstein, Katherine A; Viscoli, Catherine M; Spence, J David; Young, Lawrence H; Inzucchi, Silvio E; Gorman, Mark; Gerstenhaber, Brett; Guarino, Peter D; Dixit, Anand; Furie, Karen L; Kernan, Walter N; IRIS Trial Investigators.

in: NEUROLOGY, Jahrgang 89, Nr. 16, 17.10.2017, S. 1723-1729.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Epstein, KA, Viscoli, CM, Spence, JD, Young, LH, Inzucchi, SE, Gorman, M, Gerstenhaber, B, Guarino, PD, Dixit, A, Furie, KL, Kernan, WN & IRIS Trial Investigators 2017, 'Smoking cessation and outcome after ischemic stroke or TIA', NEUROLOGY, Jg. 89, Nr. 16, S. 1723-1729. https://doi.org/10.1212/WNL.0000000000004524

APA

Epstein, K. A., Viscoli, C. M., Spence, J. D., Young, L. H., Inzucchi, S. E., Gorman, M., Gerstenhaber, B., Guarino, P. D., Dixit, A., Furie, K. L., Kernan, W. N., & IRIS Trial Investigators (2017). Smoking cessation and outcome after ischemic stroke or TIA. NEUROLOGY, 89(16), 1723-1729. https://doi.org/10.1212/WNL.0000000000004524

Vancouver

Epstein KA, Viscoli CM, Spence JD, Young LH, Inzucchi SE, Gorman M et al. Smoking cessation and outcome after ischemic stroke or TIA. NEUROLOGY. 2017 Okt 17;89(16):1723-1729. https://doi.org/10.1212/WNL.0000000000004524

Bibtex

@article{2cac7b4a887f4f709f0c0a5943b5e9a4,

title = "Smoking cessation and outcome after ischemic stroke or TIA",

abstract = "OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking.METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized to pioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the differences in stroke, MI, and death after 4.8 years, with correction for adjustment variables prespecified in the IRIS trial: age, sex, stroke (vs TIA) as index event, history of stroke, history of hypertension, history of coronary artery disease, and systolic and diastolic blood pressures.RESULTS: At the time of their index event, 1,072 (28%) patients were current smokers. By the time of randomization, 450 (42%) patients had quit smoking. Among quitters, the 5-year risk of stroke, MI, or death was 15.7% compared to 22.6% for patients who continued to smoke (adjusted hazard ratio 0.66, 95% confidence interval 0.48-0.90).CONCLUSION: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort.",

keywords = "Aged, Cohort Studies, Female, Humans, Ischemic Attack, Transient, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Smoking, Smoking Cessation, Stroke, Journal Article",

author = "Epstein, {Katherine A} and Viscoli, {Catherine M} and Spence, {J David} and Young, {Lawrence H} and Inzucchi, {Silvio E} and Mark Gorman and Brett Gerstenhaber and Guarino, {Peter D} and Anand Dixit and Furie, {Karen L} and Kernan, {Walter N} and {IRIS Trial Investigators}",

note = "{\textcopyright} 2017 American Academy of Neurology.",

year = "2017",

month = oct,

day = "17",

doi = "10.1212/WNL.0000000000004524",

language = "English",

volume = "89",

pages = "1723--1729",

journal = "NEUROLOGY",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "16",

}

RIS

TY - JOUR

T1 - Smoking cessation and outcome after ischemic stroke or TIA

AU - Epstein, Katherine A

AU - Viscoli, Catherine M

AU - Spence, J David

AU - Young, Lawrence H

AU - Inzucchi, Silvio E

AU - Gorman, Mark

AU - Gerstenhaber, Brett

AU - Guarino, Peter D

AU - Dixit, Anand

AU - Furie, Karen L

AU - Kernan, Walter N

AU - IRIS Trial Investigators

PY - 2017/10/17

Y1 - 2017/10/17

N2 - OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking.METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized to pioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the differences in stroke, MI, and death after 4.8 years, with correction for adjustment variables prespecified in the IRIS trial: age, sex, stroke (vs TIA) as index event, history of stroke, history of hypertension, history of coronary artery disease, and systolic and diastolic blood pressures.RESULTS: At the time of their index event, 1,072 (28%) patients were current smokers. By the time of randomization, 450 (42%) patients had quit smoking. Among quitters, the 5-year risk of stroke, MI, or death was 15.7% compared to 22.6% for patients who continued to smoke (adjusted hazard ratio 0.66, 95% confidence interval 0.48-0.90).CONCLUSION: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort.

AB - OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking.METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized to pioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the differences in stroke, MI, and death after 4.8 years, with correction for adjustment variables prespecified in the IRIS trial: age, sex, stroke (vs TIA) as index event, history of stroke, history of hypertension, history of coronary artery disease, and systolic and diastolic blood pressures.RESULTS: At the time of their index event, 1,072 (28%) patients were current smokers. By the time of randomization, 450 (42%) patients had quit smoking. Among quitters, the 5-year risk of stroke, MI, or death was 15.7% compared to 22.6% for patients who continued to smoke (adjusted hazard ratio 0.66, 95% confidence interval 0.48-0.90).CONCLUSION: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort.

KW - Aged

KW - Cohort Studies

KW - Female

KW - Humans

KW - Ischemic Attack, Transient

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Proportional Hazards Models

KW - Smoking

KW - Smoking Cessation

KW - Stroke

KW - Journal Article

U2 - 10.1212/WNL.0000000000004524

DO - 10.1212/WNL.0000000000004524

M3 - SCORING: Journal article

C2 - 28887378

VL - 89

SP - 1723

EP - 1729

JO - NEUROLOGY

JF - NEUROLOGY

SN - 0028-3878

IS - 16

ER -